Details of issuance or disposal
Issuance of the 31st series of stock acquisition rights through a third-party allotment (with an exercise price adjustment clause)
4,600,000 potential shares (46,000 stock acquisition rights, each exercisable for 100 shares)
The lower thin line represents the existing number of shares to which these shares will be added.
¥1,334,000
24.96% (24.98% based on voting rights)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of the 31st series of stock acquisition rights through a third-party allotment (with an exercise price adjustment clause) |
| Number of shares to be issued or disposed of | 4,600,000 potential shares (46,000 stock acquisition rights, each exercisable for 100 shares) |
| Issue price and disposal price | ¥29 per stock acquisition right |
| Total issue value | ¥1,334,000 |
| Amount of funds to be raised | Total payment amount of ¥470,534,000; estimated net proceeds of ¥459,534,000 |
| Estimated issuance expenses | ¥11,000,000 |
| Specific use of funds | Details Research and development funding for PPMX-T004 / Amount ¥70 million / Scheduled timing of expenditures July 2027 to March 2029, Details Funding for development of the drug discovery pipeline / Amount ¥280 million / Scheduled timing of expenditures July 2027 to March 2029, Details Funding for development of AI-hybrid drug discovery / Amount ¥50 million / Scheduled timing of expenditures July 2027 to March 2029, Details Working capital / Amount ¥59 million / Scheduled timing of expenditures July 2027 to March 2029 |
| Payment date | 8 December 2026 |
| Intended allottee | Name Macquarie Bank Limited / Number of Shares 4,600,000 potential shares |
| Intended allottee's holding policy | For pure investment purposes. The common shares acquired through exercise will be sold within a relatively short period, as appropriate based on the allottee's judgment. The stock acquisition rights themselves are not scheduled to be transferred. |
| Dilution Rate | 24.96% (24.98% based on voting rights) |
| Total number of issued shares | 18,429,500 shares → 23,029,500 shares (if all rights are exercised)(24.96%) |
| Basis for determining the amount to be paid | Valued by an independent third-party valuation institution using a Monte Carlo simulation. The payment amount for the stock acquisition rights is ¥29 per right, equal to the valuation. The initial exercise price of ¥102 is 92% of the closing price of ¥111 on 19 November 2026. |
| Exercise price | Initially ¥102. Adjusted to 92% of the closing price on the trading day preceding each adjustment date. Floor of ¥56. If exercise exceeds the prescribed limit, the exercise price may not be below the closing price on the date of the issuance resolution. |
| Exercise period | 9 December 2026 to 8 December 2028 |
| Number of Stock Acquisition Rights | Total issuance of 46,000 units. The number of unexercised rights is Not disclosed. |
| Transfer restriction period | From the date of execution of this purchase agreement until the earliest of the expiration of the exercise period, completion of exercise of all rights, the date on which the company acquires all rights, or the date of termination of the agreement (subject to exceptions such as prior approval). |
| Conditions for lifting transfer restrictions | Prior approval by the company's board of directors is required, except for transfers to an affiliate of the prospective allottee. |
| Procedures under the Corporate Code of Conduct | Because the dilution rate is below 25% and the transaction does not involve a change in the controlling shareholder, obtaining an opinion from an independent third party and conducting procedures to confirm shareholders' intentions are not required. |
| Most recent equity financing | Timing 7 March 2024 / Type 28th series of stock acquisition rights through a third-party allotment / Amount Planned proceeds of ¥1,543,966,000 (estimated net proceeds), Timing 5 January 2026 / Type 29th series of stock acquisition rights through a third-party allotment / Amount Planned proceeds of ¥930,380,800 (estimated net proceeds of ¥705 million) |
| Major shareholders after the offering | The prospective allottee has not committed to long-term ownership, and no post-offering ownership percentage is disclosed. |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2027 will be immaterial, and there will be no changes to the earnings forecast. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To raise research and development funding for PPMX-T004, the drug discovery pipeline and AI-hybrid drug discovery, as well as working capital. The company cited the fact that funds raised through the 29th series of stock acquisition rights fell short of the initial estimate and its determination that additional funding was needed for new drug discovery projects and AI-hybrid drug discovery.